Report Ocean is delighted to unveil an exhaustive analysis of the Philippines Diabetes Devices Market, presenting a detailed exploration of its various dimensions from 2018 to 2032. Our in-depth study ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

As insulin prices in the United States continue to rise, making it increasingly difficult for diabetic patients to afford ...

Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...